180 related articles for article (PubMed ID: 36209987)
1. Population pharmacokinetic/pharmacodynamic analysis of PEG-rhGH enhances confidence in exploring dosing schemes with longer intervals.
Cheng R; Zhao Q; Zhong G; Xu J; Zheng Z; Xi L; Zhang M; Ni J; Hu P; Luo F; Lu W
Eur J Pharm Sci; 2022 Dec; 179():106304. PubMed ID: 36209987
[TBL] [Abstract][Full Text] [Related]
2. Reduced Effectiveness and Comparable Safety in Biweekly
Sun C; Lu B; Liu Y; Zhang Y; Wei H; Hu X; Hu P; Zhao Q; Liu Y; Ye K; Wang K; Gu Z; Liu Z; Ye J; Zhang H; Zhu H; Jiang Z; Liu Y; Wan N; Yan C; Yin J; Ying L; Huang F; Yin Q; Xi L; Luo F; Cheng R
Front Endocrinol (Lausanne); 2021; 12():779365. PubMed ID: 34899612
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I Trials.
Juul RV; Rasmussen MH; Agersø H; Overgaard RV
Clin Pharmacokinet; 2019 Jan; 58(1):63-75. PubMed ID: 29671202
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency.
Liang Y; Zhang C; Wei H; Du H; Zhang G; Yang Y; Zhang H; Gong H; Li P; Song F; Xu Z; He R; Zhou W; Zheng H; Sun L; Luo X
Front Endocrinol (Lausanne); 2022; 13():922304. PubMed ID: 36034448
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of efficacy and safety of long-acting PEGylated recombinant human growth hormone (Jintrolong) for patients with growth hormone deficiency.
Du H; Wu D; Yi P; Bai X; Luo Y; Yang H; Chen S; Pan H; Zhu H
J Pediatr Endocrinol Metab; 2022 Apr; 35(4):511-517. PubMed ID: 35245011
[TBL] [Abstract][Full Text] [Related]
6. Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies.
Luo X; Hou L; Liang L; Dong G; Shen S; Zhao Z; Gong CX; Li Y; Du ML; Su Z; Du H; Yan C
Eur J Endocrinol; 2017 Aug; 177(2):195-205. PubMed ID: 28566441
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW
Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
[TBL] [Abstract][Full Text] [Related]
8. Short-term efficacy and safety of a lower dose of polyethylene glycol recombinant human growth hormone in children with growth hormone deficiency: A randomized, dose-comparison study.
Jiang Z; Chen X; Dong G; Lou Y; Zhang J; Cheng X; Pan J; Liao W; Wu J; Huang X; Jin X; Liu D; Zeng T; Zhu S; Dong Q; Luo X; Lan D; Cao L; Zhang X; Liu J; Dai M; Zhang M; Liu L; Dong J; Zhao D; Ni S; Fu J
Front Pharmacol; 2022; 13():955809. PubMed ID: 36034802
[No Abstract] [Full Text] [Related]
9. Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children.
Hou L; Chen ZH; Liu D; Cheng YG; Luo XP
Drug Des Devel Ther; 2016; 10():13-21. PubMed ID: 26719670
[TBL] [Abstract][Full Text] [Related]
10. Long-term Pegylated GH for Children With GH Deficiency: A Large, Prospective, Real-world Study.
Hou L; Huang K; Gong C; Luo F; Wei H; Liang L; Du H; Zhang J; Zhong Y; Chen R; Chen X; Pan J; Jin X; Zeng T; Liao W; Liu D; Lan D; Zhu S; Dong Z; Ma H; Yang Y; Xiong F; Lu P; Cheng S; Gu X; Jin R; Liu Y; Wu J; Xu X; Chen L; Dong Q; Pan H; Su Z; Liu L; Luo X; Ni S; Chen Z; Hu Y; Wang C; Liu J; Liu L; Lu B; Wang X; Wang Y; Yang F; Zhang M; Cao L; Liu G; Yao H; Zhan Y; Dai M; Li G; Li L; Liu Y; Wang K; Xiao Y; Zhang X; Dong J; Gu Z; Ying L; Huang F; Liu Y; Liu Z; Ye J; Zhao D; Hu X; Jiang Z; Ye K; Zhu H; Chen S; Chen X; Wan N; Xu Z; Yin Q; Zhang H; Huang X; Yin J; Zhang H; Li P; Yin P; Fu J; Luo X
J Clin Endocrinol Metab; 2023 Jul; 108(8):2078-2086. PubMed ID: 36669772
[TBL] [Abstract][Full Text] [Related]
11. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS AND PATIENTS TRANSITIONING FROM PEDIATRIC TO ADULT CARE.
Yuen KCJ; Biller BMK; Radovick S; Carmichael JD; Jasim S; Pantalone KM; Hoffman AR
Endocr Pract; 2019 Nov; 25(11):1191-1232. PubMed ID: 31760824
[No Abstract] [Full Text] [Related]
12. Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency.
Søndergaard E; Klose M; Hansen M; Hansen BS; Andersen M; Feldt-Rasmussen U; Laursen T; Rasmussen MH; Christiansen JS
J Clin Endocrinol Metab; 2011 Mar; 96(3):681-8. PubMed ID: 21177789
[TBL] [Abstract][Full Text] [Related]
13. Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children.
Cohen P; Germak J; Rogol AD; Weng W; Kappelgaard AM; Rosenfeld RG;
J Clin Endocrinol Metab; 2010 May; 95(5):2089-98. PubMed ID: 20207829
[TBL] [Abstract][Full Text] [Related]
14. [Effect of recombinant human growth hormone on glucose metabolism in children with growth hormone deficiency].
Liang L; Zou CC; Li Y; Wang CL; Jiang YJ; Dong GP; Fu JF; Wang XM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):657-61. PubMed ID: 17217656
[TBL] [Abstract][Full Text] [Related]
15. Responses to growth hormone (GH) therapy in short children with normal GH secretion and no bone age delay: an analysis of potential factors affecting their response to rhGH therapy. A controlled study.
Soliman AT; Elawwa A; Itani M; Jour C; De Sanctis V
Acta Biomed; 2019 Sep; 90(8-S):43-51. PubMed ID: 31544806
[TBL] [Abstract][Full Text] [Related]
16. [The effect of one year of recombinant human growth hormone (rhGH) therapy on left ventricle structure and function in adults with severe growth hormone deficiency].
Płońska E; Krzyzanowska-Swiniarska B; Gruszczyńska M; Pynka S; Lewandowski M; Kornacewicz-Jach Z; Pilarska K
Pol Merkur Lekarski; 2006 Apr; 20(118):386-9. PubMed ID: 16886557
[TBL] [Abstract][Full Text] [Related]
17. Growth response to growth hormone (GH) treatment in children with GH deficiency (GHD) and those with idiopathic short stature (ISS) based on their pretreatment insulin-like growth factor 1 (IGFI) levels and at diagnosis and IGFI increment on treatment.
Soliman A; Rogol AD; Elsiddig S; Khalil A; Alaaraj N; Alyafie F; Ahmed H; Elawwa A
J Pediatr Endocrinol Metab; 2021 Oct; 34(10):1263-1271. PubMed ID: 34291621
[TBL] [Abstract][Full Text] [Related]
18. Long-acting PEGylated growth hormone in children with idiopathic short stature.
Luo X; Zhao S; Yang Y; Dong G; Chen L; Li P; Luo F; Gong C; Xu Z; Xu X; Gong H; Du H; Hou L; Zhong Y; Shi Q; Chen X; Chen X; Xu L; Cheng R; Su C; Ma Y; Xu L; Zhang L; Lu H
Eur J Endocrinol; 2022 Nov; 187(5):709-718. PubMed ID: 36130048
[TBL] [Abstract][Full Text] [Related]
19. PEGylated Recombinant Human Growth Hormone Jintrolong
Wu W; Zhou J; Wu C; Zhou Q; Li X; Zhang Y; Zuo C; Yin J; Hou L; Wang S; Gao H; Luo T; Jin L; Zhong E; Wang Y; Luo X
Front Endocrinol (Lausanne); 2022; 13():821588. PubMed ID: 35909512
[TBL] [Abstract][Full Text] [Related]
20. Circulating IGF-I, IGFBP-3 and the IGF-I/IGFBP-3 Molar Ratio Concentration and Height Outcome in Prepubertal Short Children on rhGH Treatment over Two Years of Therapy.
Ballerini MG; Braslavsky D; Scaglia PA; Keselman A; Rodríguez ME; Martínez A; Freire AV; Domené HM; Jasper HG; Bergadá I; Ropelato MG
Horm Res Paediatr; 2017; 88(5):354-363. PubMed ID: 28926833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
